Home Online Features NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
Press Releases
December 30, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

By NRx Pharmaceuticals, Inc.

Aiming to be the first FDA-approved medication to treat suicidal depressionDesigned to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC)Completion

bradford

The Bradford Era

email
More by this Author
Local & Social